Welcome to our dedicated page for SILICON LABORATORIES SEC filings (Ticker: SLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silicon Laboratories Inc. filings document an operating semiconductor company focused on low-power wireless connectivity, embedded SoCs and security technology for edge devices. Its 8-K reports cover operating results, financial condition, non-GAAP measures, material-event disclosures, capital-structure items, material agreements and solicitation materials tied to shareholder matters.
Proxy and annual meeting filings disclose board elections, auditor ratification, executive compensation votes and amendments to the 2009 Stock Incentive Plan. The filings also identify the company’s Nasdaq-listed common stock and provide formal records of governance actions, equity-plan matters and stockholder voting outcomes.
Silicon Laboratories Inc. reports higher Q1 revenue but remains unprofitable while progressing toward an all-cash sale to Texas Instruments. Revenue for the quarter ended April 4, 2026 rose to $213.5 million from $177.7 million, driven by strong Industrial & Commercial and Home & Life demand. Gross margin improved to 59.5%, and the net loss narrowed to $15.9 million, or $0.48 per share, compared with a $30.5 million loss a year earlier.
Cash, cash equivalents and short-term investments totaled $438.9 million, with positive operating cash flow of $4.9 million and no borrowings on a $400 million revolving credit facility. The company entered into a Merger Agreement under which each share will be converted into the right to receive $231.00 in cash, subject to customary closing conditions, with closing expected in the first half of 2027. Silicon Labs recorded $11.2 million of merger-related costs in the quarter and highlights ongoing macroeconomic and geopolitical risks, as well as regulatory and closing risks related to the proposed transaction.
Silicon Laboratories Inc. reported first-quarter 2026 results with revenue of $213.5 million and non-GAAP diluted earnings per share of $0.53. Revenue grew 20% year-over-year, led by Industrial & Commercial revenue of $128 million, up 33%, and Home & Life revenue of $86 million, up 5%.
On a GAAP basis, the company posted a net loss of $15.9 million, or $0.48 per diluted share, with a GAAP gross margin of 59.5%. Non-GAAP operating income was $18.1 million with a 59.7% non-GAAP gross margin. Silicon Labs ended the quarter with $383.1 million in cash and cash equivalents and has suspended forward-looking guidance due to the pending acquisition by Texas Instruments.
Silicon Laboratories Inc. Chief Accounting Officer Mark D. Mauldin acquired 18 shares of common stock on the issuer’s employee purchase date at a price of $86.46 per share. After this transaction, he directly holds 21,948 common shares.
The shares were acquired through Silicon Laboratories’ 2009 Employee Stock Purchase Plan in a transaction described as exempt under Rule 166-3(c) and Rule 166-3(d), indicating this was a routine, compensation-related purchase rather than an open-market trade.
Silicon Laboratories Inc. senior vice president of worldwide sales and marketing Brandon Tolany acquired 45 shares of common stock on the most recent semi-annual purchase date. The shares were obtained at $86.46 per share through the company’s 2009 Employee Stock Purchase Plan in a transaction described as a grant or award acquisition. After this routine plan-based acquisition, Tolany directly owns 71,095 shares of Silicon Laboratories common stock.
SILICON LABORATORIES INC. Senior Vice President and CFO Dean Warren Butler acquired additional common stock through the company’s 2009 Employee Stock Purchase Plan. He received 152 shares of common stock at $86.46 per share on the most recent semi-annual purchase date, bringing his directly held stake to 50,058 shares. The acquisition is described as a transaction exempt under Rule 166-3(c) and Rule 166-3(d), indicating it is a routine, compensation-related share purchase rather than an open-market trade.
Silicon Laboratories Inc reported a Schedule 13G identifying Vanguard Capital Management as beneficial owner of 1,725,524 shares of Common Stock, representing 5.23% of the class as of 03/31/2026.
The filing states Vanguard has sole voting power for 252,194 shares and sole dispositive power for 1,725,524 shares. The filing clarifies these holdings include securities held by Vanguard funds and certain affiliated business divisions; no single other person holds >5% of the class according to the disclosure.
Silicon Laboratories Inc. held a special stockholder meeting where investors approved the proposed merger with Texas Instruments Incorporated, under which Silicon Labs will become a wholly owned subsidiary of Texas Instruments after closing conditions are met. The merger proposal passed with 25,878,105 votes in favor, 7,467 against and 1,570 abstentions, representing a strong majority of shares present. Stockholders also approved, on a non-binding advisory basis, the compensation tied to the merger for Silicon Labs’ named executive officers. A separate adjournment proposal was rendered moot because a quorum was present and sufficient votes were already received to adopt the merger agreement.
Vanguard Portfolio Management reports beneficial ownership of 2,167,187 shares of Silicon Laboratories Inc. The filing shows Vanguard holds 2,167,187 shares, representing 6.57% of the outstanding common stock as of 03/31/2026. Vanguard reports sole voting power for 28,351 shares and sole dispositive power for 2,167,187 shares, and states these holdings include securities held for Vanguard funds and managed accounts.
Wyatt Christy reported acquisition or exercise transactions in this Form 4 filing.
SILICON LABORATORIES INC. director Christy Wyatt received a grant of 962 restricted stock units (RSUs), each representing one share of common stock. After this award, Wyatt directly holds 9,454 common shares. The RSUs will fully vest on the earlier of the first anniversary of the grant date or one day before the next year’s Annual Meeting of Stockholders.